Monoclonal Antibody Diagnostic Reagents Market Growing at a Steady CAGR to 2026
Different monoclonal
antibodies with unique mechanism of actions have been approved over
the past few years, which work on immune checkpoints such as CTLA-4,
PD-1, and PD-L1. Manufacturers are focusing on developing drugs
belonging to various classes in order to treat variety of diseases
ranging from cancer to rare diseases. Monoclonal antibody coupled
with chemotherapy agents is becoming a viable treatment option to
treat various cancers. For instance, in 2017, the U.S. Food &
Drug Administration (FDA) approved Darzalex (daratumumab) in
combination with pomalidomide and dexamethasone for the treatment of
patients suffering from multiple myeloma, who have received two prior
therapies. These factors are expected to support growth of the market
over the forecast period.
Get Exclusive
Sample Report at: http://bit.ly/2WL3Mn1
Market Dynamics
Monoclonal antibody
therapeutics market is driven by active research and development of
novel drugs and significant number of new drug launches and approval.
There are number of monoclonal antibodies in the pipeline, which are
expected to receive approval over the forecast period. For instance,
manufacturers such as Amgen, Inc., Novartis International AG, Merck &
Co., Inc., Eily, Lilly, and Company, and others have several
monoclonal antibodies in the pipeline. Moreover, efforts of
manufacturers to increase number of indications (oncology) for
monoclonal antibodies is further expected to boost the market growth
over the forecast period. For instance, in June 2018, the U.S. Food &
Drug Administration (FDA), expanded the indication of pembrolizumab
(Keytruda) to include recurrent or metastatic cervical cancer with
disease progression on or after chemotherapy.
Increasing Drug
Approvals And Launch Of Novel Monoclonal Antibodies For Treatment Of
Various Diseases Such As Cancer Are Expected To Boost The Market
Growth Over The Forecast Period
Frequent approvals
of novel monoclonal antibodies and their launches in developed
economies are expected to significantly drive monoclonal antibody
therapeutics market growth over the forecast period. Key players in
the market have gained regulatory approvals and have launched their
therapies in the market. For instance, in 2015, the U.S. FDA approved
Darzalex, developed by Johnson & Johnson for multiple myeloma.
Similarly, in 2017, Roche was granted accelerated approval to
TECENTRIQ (atezolizumab) from the U.S FDA for the treatment of people
with locally advanced or metastatic urothelial carcinoma (mUC) who
are not eligible for cisplatin chemotherapy.
Ongoing Research
And Development Of Monoclonal Antibodies For Various Diseases Is
Expected To Boost Growth Of The Global Monoclonal Antibody
Therapeutics Market
Introduction and
supposed success of monoclonal antibodies and other biological
products has spurred the interest of manufacturers in these
therapies. Success of popular monoclonal antibodies such as Avastin,
Herceptin, and Rituxan (revenues as US$ 6.8 Bn, US$ 7.1 Bn, and US$
5.9 Bn respectively in 2017 globally) has spurred manufacturers’
interest in these therapies. Leading manufacturers have resorted to
boosting pipeline through various ways such as merger and
acquisitions, partnerships, and collaboration. In 2016, AbbVie
acquired Stemcentrx thereby adding rovalpituzumab tesirine (Rova-T)
to its product portfolio in oncology segment. Cancer treatment
(various types) is at the forefront of the monoclonal antibody
research as leading manufacturers are focused on development of these
drugs for cancer treatment. For instance, manufacturers such as
Amgen, Inc. (e.g. Tezepelumab and others) and Novartis International
AG (e.g. Ofatumumab and others) have several monoclonal antibody
programs in the pipeline.
However, high costs
of these products is a major concern (in regions with underdeveloped
reimbursement facilities) in the healthcare system and to address
this problem, manufacturers have resorted to biosimilar products.
Biosimilars cost much lower than the original products as the cost of
development is relatively low. Majority of the available monoclonal
antibody therapeutics (cancer treatments) are expected to lose patent
protection by 2020 and some by 2025. For instance, drugs such as
Herceptin and Avastin are expected to lose patent protection in 2019.
These factors are expected to restrain the global monoclonal antibody
therapeutics market growth over the forecast period.
Inquire Here
Before Purchase of Research Report @ http://bit.ly/2KqKMUD
Some of the major
players operating in the global monoclonal antibody therapeutics
market include, Pfizer, Inc., Novartis International AG, Amgen, Inc.,
Sanofi S.A., Merck & Co., Inc., GlaxoSmithKline Plc., F.
Hoffmann-La Roche Ltd., AbbVie, Inc., Eily, Lilly, and Company, and
Bristol-Myers Squibb Company.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment